Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,673.72
(
-0.63%
)
US TECH 100
23,954.40
(
-0.74%
)
Dow Jones
46,560.26
(
-0.92%
)
Brent Oil
104.20
(
3.53%
)
Bitcoin
71,713.86
(
-3.01%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 131470

Monday, 02/27/2012 11:34:24 PM

Monday, February 27, 2012 11:34:24 PM

Post# of 257253
FDA grants priority review for Xarelto in ACS:

http://www.reuters.com/article/2012/02/27/jj-xarelto-idUSL4E8DRAC420120227

I’m a little surprised at the FDA’s decision here. The PDUFA date is in Jun 2012.

I previously opined—and continue to believe—that Xarelto will not take any significant market share from Lovenox in this indication (#msg-69172520).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now